TGF-β: A novel predictor and target for anti-PD-1/PD-L1 therapy
Open Access
- 19 December 2022
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 13, 1061394
Abstract
Transforming growth factor-β (TGF-β) signaling regulates multiple physiological processes, such as cell proliferation, differentiation, immune homeostasis, and wound healing. Besides, TGF-β plays a vital role in diseases, including cancer. Accumulating evidence indicates that TGF-β controls the composition and behavior of immune components in the tumor microenvironment (TME). Advanced cancers leverage TGF-β to reshape the TME and escape immune surveillance. TGF-β-mediated immune evasion is an unfavorable factor for cancer immunotherapy, especially immune checkpoint inhibitors (ICI). Numerous preclinical and clinical studies have demonstrated that hyperactive TGF-β signaling is closely associated with ICI resistance. It has been validated that TGF-β blockade synergizes with ICI and overcomes treatment resistance. TGF-β-targeted therapies, including trap and bispecific antibodies, have shown immense potential for cancer immunotherapy. In this review, we summarized the predictive value of TGF-β signaling and the prospects of TGF-β-targeted therapies for cancer immunotherapy.Keywords
Funding Information
- National Natural Science Foundation of China (82073370, 82073370, 81874120)
- China Postdoctoral Science Foundation (2022M722766)
This publication has 148 references indexed in Scilit:
- A human monoclonal antibody 264RAD targeting αvβ6 integrin reduces tumour growth and metastasis, and modulates key biomarkers in vivoOncogene, 2012
- LY2109761 Attenuates Radiation-Induced Pulmonary Murine Fibrosis via Reversal of TGF-β and BMP-Associated Proinflammatory and Proangiogenic SignalsClinical Cancer Research, 2012
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerNew England Journal of Medicine, 2012
- Targeted therapy for high-grade glioma with the TGF- 2 inhibitor trabedersen: results of a randomized and controlled phase IIb studyNeuro-Oncology, 2010
- Phase II trial of Belagenpumatucel-L, a TGF-β2 antisense gene modified allogeneic tumor vaccine in advanced non small cell lung cancer (NSCLC) patientsCancer Gene Therapy, 2009
- Targeted tumor therapy with the TGF-β2 antisense compound AP 12009Cytokine & Growth Factor Reviews, 2006
- TGF-β directly targets cytotoxic T cell functions during tumor evasion of immune surveillanceCancer Cell, 2005
- Smad-dependent and Smad-independent pathways in TGF-β family signallingNature, 2003
- New applications of gemcitabine and future directions in the management of pancreatic cancerCancer, 2002
- Anti-transforming growth factor (TGF)-beta antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity. Implications for a possible role of tumor cell/host TGF-beta interactions in human breast cancer progression.Journal of Clinical Investigation, 1993